Bifogade filer
20240110 PM Isofol - New CFO_final
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
The information in the press release is intended for investors.
Magnus Hurst has long experience in financial roles at companies such as SAS and within the Kinnevik Group. He currently holds a position as CFO and Head of Investor Relations at the biotech company Synartro and will combine this role with the new assignment as CFO at Isofol.
Magnus holds an M.Sc. in Finance from Bayes Business School, UK, as well as a B.Sc. in Business Studies and an LL.M from Uppsala University, Sweden.
Magnus Hurst succeeds Roy Jonebrant, who has been acting CFO on a consultacy basis since March 2023 and whose contract expires at the end of January 2024.
"I look forward to working together with Magnus and welcome him as CFO. I am convinced that his solid background and experience will strengthen Isofol. I also want to thank Roy for his valuable contribution as acting CFO," says Isofol's CEO, Petter Segelman Lindqvist.
For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, CEO
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0) 739 60 12 56
The information was submitted for publication, through the agency of the contact persons set out above, at 20:30 CET on January 10, 2024.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.